Digital Therapeutics & Prescription Apps
Software is becoming the new medicine. These carefully selected companies are developing FDA-cleared applications that treat everything from mental health to diabetes. With growing insurance reimbursement and massive scalability, these digital treatments represent healthcare's next frontier.
Your Basket's Financial Footprint
Summary of total market capitalisation and constituent breakdown for the Digital Therapeutics & Prescription Apps basket.
- Large-cap dominance implies generally lower volatility and more stable, market-tracking performance compared with smaller-cap-focused baskets.
- Suitable as a core holding: adds broad sector exposure, not recommended as a speculative, short-term trade.
- Expect steady, long-term value; unlikely to deliver rapid, explosive short-term gains.
DRIO: $51.25M
GDRX: $1.35B
TDOC: $1.53B
- Other
About This Group of Stocks
Our Expert Thinking
Digital therapeutics represent a fundamental shift in healthcare delivery. These clinically-validated software programs are designed to prevent, manage, or treat medical conditions without traditional drugs or devices. As healthcare embraces technology, these scalable solutions promise better patient outcomes at lower costs.
What You Need to Know
This is an emerging, high-growth sector with significant potential but also substantial risk. Insurance reimbursement is the critical catalyst for widespread adoption. Companies range from pure-play digital therapeutics developers to larger telehealth platforms incorporating these technologies into broader offerings.
Why These Stocks
We've selected companies directly involved in creating or delivering software-based medical treatments. This includes dedicated digital therapeutics developers, telehealth platforms enabling digital prescriptions, and companies creating complementary technologies that support this emerging ecosystem.
Why You'll Want to Watch These Stocks
Software Is Becoming Medicine
These companies are creating FDA-cleared apps that actually treat diseases. It's a whole new category of medicine where code itself becomes the treatment—potentially reaching millions of patients at a fraction of traditional costs.
Insurance Companies Are Paying Up
The big breakthrough? Insurance providers are increasingly willing to reimburse for these digital therapies. This payment validation could trigger explosive growth as these treatments become mainstream healthcare options.
Early Days of a Healthcare Revolution
We're just at the beginning of software-as-medicine. With chronic diseases, mental health conditions, and preventative care all being targeted, these companies are pioneering what could become a multi-billion dollar healthcare category.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Tech Stocks (AI Valuation Reset) Present Potential Entry
Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.
Walmart Succession Plan Explained | Market Effects
Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.
Biotech Buyout Candidates (Post-Merck Acquisition)
Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.